Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

CBD has shown promise as a treatment for psychosis in small studies and case reports. A large, international trial launching ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three for oncology, a weekly insulin, and innovations in obesity, hemophilia, ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

Meanwhile, Bristol-Myers Squibb (BMY) sees potential in its schizophrenia drug, Cobenfy, as a future Alzheimer's treatment. "We're So Doomed": People Are Sharing Their Unfiltered Reactions To RFK ...

BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.